U.S. markets closed

Virax Biolabs Group Limited (VRAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.1500+0.0700 (+2.27%)
At close: 04:00PM EDT
3.2000 +0.05 (+1.59%)
After hours: 07:29PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close3.0800
Bid3.1200 x 800
Ask3.2000 x 800
Day's Range3.0400 - 3.2000
52 Week Range2.4200 - 29.0000
Avg. Volume4,215,962
Market Cap35.828M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VRAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virax Biolabs Group Limited
    Daily – Vickers Top Buyers & Sellers for 09/13/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    18 days agoArgus Research
View more
  • Benzinga

    EXCLUSIVE: Newly Listed Virax Biolabs Launches Monkeypox Antigen Rapid Test

    Virax Biolabs Group Ltd (NASDAQ: VRAX) has announced the distribution of a Monkeypox Antigen Rapid Test Kit launched in the European markets accepting the CE mark. The specialized diagnostic kits can be found by contacting the company’s sales representatives. Founded in 2013, in July 2022, Virax Biolabs concluded its initial public offering of 1.35 million shares at $5.00 per share, for total gross proceeds of $6.75 million. The test kits are for use in point-of-care settings. They can help heal

  • Motley Fool

    Why Virax Biolabs Stock Plummeted 74% On Friday

    Shares of Virax Biolabs (NASDAQ: VRAX) dropped 74% on Friday. The biotech company, which specializes in the detection and treatment of viral diseases, just began trading on the NASDAQ on July 21 after an initial public offering (IPO).